Head-To-Head Comparison: DeFi Technologies (NASDAQ:DEFT) & BR Biopharma (NASDAQ:BRBI)

DeFi Technologies (NASDAQ:DEFT) and BR Biopharma (NASDAQ:BRBI) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Earnings and Valuation

This table compares DeFi Technologies and BR Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DeFi Technologies	$99.14 million	1.43	$62.41 million	$0.06	6.10
BR Biopharma	$12.34 billion	0.01	$31.36 million	$0.08	92.44

DeFi Technologies has higher earnings, but lower revenue than BR Biopharma. DeFi Technologies is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for DeFi Technologies and BR Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DeFi Technologies	0	2	3	0	2.60
BR Biopharma	1	1	0	0	1.50

DeFi Technologies currently has a consensus price target of $1.44, indicating a potential upside of 292.65%. Given DeFi Technologies’ stronger consensus rating and higher probable upside, research analysts clearly believe DeFi Technologies is more favorable than BR Biopharma.

Profitability

This table compares DeFi Technologies and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DeFi Technologies	39.65%	15.43%	2.64%
BR Biopharma	N/A	N/A	N/A

Summary

DeFi Technologies beats BR Biopharma on 8 of the 11 factors compared between the two stocks.

About DeFi Technologies

DeFi Technologies, Inc. engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. The firm offers DeFi ETNs, DeFi Governance, DeFi Venture and DeFi Treasury. The company was founded by Olivier Francois Roussy Newton and Wouter Witvoet on April 14, 1986 and is headquartered in Toronto, Canada.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.